三重激动剂 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-26. Anything still debated is marked as such rather than presented as settled.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
=== Historic and laboratory routes === Fumaric acid was first prepared from succinic acid. A traditional synthesis involves oxidation of furfural (from the processing of maize) using chlorate in the presence of a vanadium-based catalyst.
Physical and chemical properties of the drug. The physical properties are solid, liquid and gas. The chemical properties are solubility, stability, pH, irritancy, etc. Site of desired action: the action may be localised and approachable or generalised and not approachable. Rate of extent of absorption of the drug from different routes. Effect of digestive juices and the first pass metabolism of drugs. Condition of the patient. In acute situations, in emergency medicine and intensive care medicine, drugs are most often given intravenously. This is the most reliable route, as in acutely ill patients the absorption of substances from the tissues and from the digestive tract can often be unpredictable due to altered blood flow or bowel motility.
=== Toxicity === C-4 has toxic effects on humans when ingested. Within a few hours multiple generalized seizures, vomiting, and changes in mental activity occur. A strong link to central nervous dysfunction is observed. If ingested, patients may be administered a dose of active charcoal to adsorb some of the toxins, and haloperidol intramuscularly and diazepam intravenously to help the patient control seizures until it has passed. However, ingesting small amounts of C-4 is not known to cause any long-term impairment.
In 1933, the French pharmaceutical company Laboratoires Rhône-Poulenc began to search for new antihistamines. In 1947, it synthesized promethazine, a phenothiazine derivative, which was found to have more pronounced sedative and antihistaminic effects than earlier drugs. A year later, the French surgeon Pierre Huguenard used promethazine together with pethidine as part of a cocktail to induce relaxation and indifference in surgical patients. Another surgeon, Henri Laborit, believed the compound stabilized the central nervous system by causing "artificial hibernation" and described this state as "sedation without narcosis". He suggested to Rhône-Poulenc that they develop a compound with better-stabilizing properties. In December 1950, the chemist Paul Charpentier produced a series of compounds that included RP4560 or chlorpromazine. Chlorpromazine was distributed for testing to physicians between April and August 1951. Laborit trialled the medicine at the Val-de-Grâce military hospital in Paris, using it as an anaesthetic booster in intravenous doses of 50 to 100 mg in surgery patients and confirming it as the best drug to date in calming and reducing shock, with patients reporting improved well being afterward. He also noted its hypothermic effect and suggested it may induce artificial hibernation. Laborit thought this would allow the body to better tolerate major surgery by reducing shock, a novel idea at the time. Following on, Laborit considered whether chlorpromazine may have a role in managing patients with severe burns, Raynaud's phenomenon, or psychiatric disorders.
Sources: en.wikipedia.org
TKIs target KIT and can deplete the number of mast cells, but inhibit other tyrosine kinases as well causing side effects. The TKI midostaurin, which has multiple targets, was approved for the treatment of advanced systemic mastocytosis (ASM) in 2017. Avapritinib was approved for ASM in 2021. Anti-KIT mAbs also have been evaluated in chronic urticaria and are reported to reduce symptoms. They appear to induce MC deficiency and reduce serum tryptase.
Therefore, hyperhomocysteinemia is a possible risk factor for coronary artery disease. Coronary artery disease occurs when an atherosclerotic plaque blocks blood flow to the coronary arteries, which supply the heart with oxygenated blood. Hyperhomocysteinemia has also been correlated with the occurrence of blood clots, heart attacks, and strokes, although it is unclear whether hyperhomocysteinemia is an independent risk factor for these conditions. Hyperhomocysteinemia has also been associated with early-term spontaneous abortions and with neural tube defects.
== External links == Labor Management Relations Act (PDF/details) as amended in the GPO Statute Compilations collection A film clip "Longines Chronoscope with Fred A Hartley" is available for viewing at the Internet Archive
== Urban hydroponics == Urban hydroponics refers to the use of soilless cultivation systems in city environments, including apartments, rooftops, and other indoor spaces. These systems have been explored in response to challenges related to urban food access. According to the United States Department of Agriculture, more than 19 million people in the United States live in low-income neighborhoods with limited access to supermarkets or large grocery stores, areas often referred to as food deserts. In these contexts, hydroponic systems can be used as a method to grow vegetables such as lettuce, spinach, and herbs indoors. Urban hydroponic systems are generally designed to operate within small spaces. Commercially available units include vertical towers, countertop kits, and window-mounted structures, many of which rely on artificial lighting and water circulation to deliver nutrients directly to plant roots. These configurations are intended to support plant growth in environments with limited natural sunlight and no access to soil. Some hydroponic systems are marketed toward individual consumers and households. While larger systems may require significant investment, smaller-scale models are available for individual use. Reports suggest that such systems can produce a range of crops year-round, though yield and cost-efficiency vary by setup and user experience. Hydroponic systems have also been studied for their resource efficiency.
TAP is a heterodimeric complex, consisting of TAP1 (ABCB2) and TAP2 (ABCB3) members of the ABC transporter superfamily. The common feature of all ABC transporters is their organization: 1) into two transmembrane domains (TMDs) and 2) into two nucleotide-binding domains (NBDs). Both intramolecular domains are coupled to each other and when ATP binding is in progress, conformational changes in the TMDs allow proteasomal degradation products to move across the membrane. TAP recognizes and transports the antigen peptides produced in the cytosol straight into the ER, while tapasin recognizes the kind of peptides that have the ability to form stable complexes with MHC-I. This process is known as peptide proofreading or editing. Peptides selected through proofreading improve MHC-I stability; tapasin also contributes to the editing of immunogenic peptide epitopes. However, only lately it was proven via biochemical, biophysical, and structural studies that a key function in adaptive immunity, the catalytic mechanism of peptide proofreading, is performed by tapasin and TAPBPR (TAP-binding protein-related, a tapasin homologue).
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.